Ian Clark
About Ian Clark
Ian Clark, 64, has served on Olema’s Board since August 2020 and is the independent Chairperson. He was CEO of Genentech (2010–2016) after senior commercial and BioOncology leadership roles, and previously spent ~20 years in leadership positions at Novartis, Sanofi, Ivax, and G.D. Searle. He holds a B.S. in Biological Sciences and an Honorary Doctorate of Science from Southampton University (UK). The Board deems him independent under Nasdaq standards.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Genentech, Inc. | Chief Executive Officer; member of board; led executive committee | Jan 2010–Dec 2016 | Led commercial strategy and operations; member of executive committee for 12 years |
| Genentech, Inc. | EVP, Commercial Operations; SVP & GM BioOncology | Pre-2010 | Senior commercial and oncology market leadership |
| Novartis; Sanofi; Ivax; G.D. Searle | Senior roles (in UK, Canada, Eastern Europe, France) | ~20 years (pre‑Genentech) | Multinational pharma leadership across geographies |
External Roles
| Organization | Role | Start/End | Notes |
|---|---|---|---|
| GoodRx Holdings, Inc. | Director | Since Jul 2024 | Current public board |
| Kyverna Therapeutics, Inc. | Director | Since Sep 2021 | Current public board |
| Takeda Pharmaceutical Co. Ltd. | Director | Since Jan 2019 | Current public board |
| Corvus Pharmaceuticals, Inc. | Director | Since Jan 2017 | Current public board |
| Guardant Health, Inc. | Director | Since Jan 2017 | Current public board |
| AVROBIO, Inc. | Director | Jan 2018–Jun 2024 | Ended after transaction with Tectonic Therapeutics |
| Shire Pharmaceuticals, Inc. | Director | Feb 2017–Jan 2019 | Ended upon Takeda acquisition |
| Kite Pharma, Inc. | Director | Jan–Oct 2017 | Pre-acquisition board service |
| Forty Seven Inc. | Director | May 2018–Apr 2020 | Pre-acquisition board service |
| Agios Pharmaceuticals, Inc. | Director | Dec 2016–Jun 2022 | Prior public board |
| Gyroscope; TerraVia; Dendreon; Vernalis | Director | Prior | Historical board service |
| KKR & Co. Inc. | Advisor | Current | Prior advisory roles at Lazard, Blackstone Life Sciences, Perella Weinberg |
Board Governance
- Independence: Independent director under Nasdaq standards; independent Chairperson.
- Committee assignments (2024): Chair, Nominating & Corporate Governance Committee; not on Audit or Compensation Committees.
- Attendance: 100% Board meeting attendance in 2024; Board met eight times; independent directors held three executive sessions presided over by the Chair.
- Years of service: Director since 2020; current Class I term expires in 2027.
Fixed Compensation
| Component | Amount/Policy | Effective date |
|---|---|---|
| Annual director cash retainer | $40,000 | |
| Additional cash retainer – Chair of Board | $30,000 | |
| Committee member retainers | Audit $8,000; Compensation $6,000; Nominating & Corporate Governance $5,000 | |
| Committee chair retainers | Audit $10,750; Compensation $6,000; Nominating & Corporate Governance $5,000 | |
| Amended committee retainers (members) | Audit $10,000; Compensation $7,500 (effective July 1, 2025) | |
| Amended committee retainers (chairs) | Audit $10,000; Compensation $7,500 (effective July 1, 2025) | |
| Ian Clark – 2024 compensation | Fees earned: $80,000; Option awards (grant-date fair value): $200,790; Total: $280,790 |
Performance Compensation
| Equity Award | Grant size | Vesting | Notes |
|---|---|---|---|
| Annual director option (pre‑2024 policy) | 21,520 shares | Earlier of 1 year or next annual meeting; 10-year term | 2020 policy (amended April 2024) |
| Annual director option (2024 policy) | 23,000 shares | Earlier of 1 year or next annual meeting; 10-year term | Effective June 1, 2024 |
| Initial director option (2024 policy) | 23,000 shares (+ prorated annual grant) | Same as above | At appointment/election |
| Annual/Initial options (2025 policy) | 24,150 shares | Same vesting; 10-year term | Adopted March 18, 2025 (cash changes effective July 1, 2025) |
No director performance metrics (TSR/EBITDA/ESG) are tied to director equity; grants are time-based options with standard vesting to the next annual meeting.
Other Directorships & Interlocks
| Company | Sector overlap with Olema | Potential interlock/conflict |
|---|---|---|
| Guardant Health; Corvus; Kyverna; Takeda | Biopharma/oncology | Sector overlap; no Olema-related party transactions disclosed involving Ian Clark – |
| GoodRx | Healthcare technology | No Olema-related party transactions disclosed involving Ian Clark – |
Expertise & Qualifications
- Biopharma commercial and CEO experience (Genentech leadership, broad global pharma roles) .
- Governance expertise as independent Chair and Nominating & Corporate Governance Committee chair .
- Education: B.S. Biological Sciences; Honorary Doctorate of Science (Southampton University, UK) .
Equity Ownership
| Holder | Beneficial ownership (shares) | % of outstanding | Notes |
|---|---|---|---|
| Ian Clark | 318,770 shares issuable upon options exercisable within 60 days (as of Apr 21, 2025) | <1% | Reflects options; no direct share holdings disclosed; non-employee director |
| Options outstanding (as of Dec 31, 2024) | 318,770 | — | Aggregate options held by Ian Clark |
| Hedging/pledging | Prohibited under Insider Trading Policy | — | Applies to directors (alignment-positive) |
Governance Assessment
- Strengths
- Independent Chair with deep oncology and commercial leadership; chairs Nominating & Corporate Governance Committee, supporting board composition and evaluation rigor.
- High engagement: 100% attendance; presides over executive sessions of independent directors.
- Transparent, standardized director pay and equity, with options vesting to next annual meeting; clawback policy in place for executives; hedging/pledging ban applies to directors.
- Shareholder support for compensation and governance (say‑on‑pay passed with ~98% in 2024; ~90% in 2023).
- Risks/RED FLAGS
- Multi‑board commitments: Serves (or recently served) on six public boards; company asserts sufficient time and notes 100% attendance, but concentration across biopharma could create potential informational conflicts; monitoring is warranted.
- Sector overlap: Multiple oncology/pharma boards raise theoretical conflict exposure; Olema’s related‑party disclosures do not identify transactions involving Ian Clark, and a related party transactions policy requires Audit Committee review and recusal where applicable. –
- Net view: Governance quality appears robust with independent leadership, active participation, and clear compensation/insider policies; primary watchpoint is multi‑board load and sector overlaps.
No delinquent Section 16 filings identified for Ian Clark in 2024; proxy cites only an amended Form 4 for another director.
